Sandoz Omnitrope NDA Is Test For Follow-On Biologics; Pfizer Says No

Sandoz' pending NDA for Omnitrope appears ripe for an FDA decision

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet